Limits...
Enhanced production of IGF-I in the lungs of fibroproliferative ARDS patients.

Andonegui G, Krein PM, Mowat C, Brisebois R, Doig C, Green FH, Léger C, Winston BW - Physiol Rep (2014)

Bottom Line: Our data show that IGF-I is significantly increased in the ELF in FP-ARDS patients.A significant correlation between IGF-I and PCP-III in the ELF of FP-ARDS patients is found.Our data suggest that IGF-I found in the lungs of FP-ARDS patients results from both increased lung permeability and local production of IGF-I.

View Article: PubMed Central - PubMed

Affiliation: Department of Critical Care Medicine, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada Immunology Research Group, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus

Free (Active) IGF‐I Protein Levels in ELF and Serum. Free IGF‐I protein levels were measured in BALF and serum by RIA. ELF concentration was calculated using the urea method to correct for BAL dilution as described in Materials and Methods. (A) Free IGF‐I protein levels are elevated in FP‐ARDS ELF (n = 14) versus control individuals (n = 11), *P < 0.05, 95% CI and versus early ALI/ARDS ELF (n = 11), #P < 0.05, 95% CI. (B) In early ALI/ARDS serum (n = 11) free IGF‐I protein levels increase significantly compared to control (n = 11), *P < 0.0001 and FP‐ARDS patients (n = 14) #P < 0.0001. In FP‐ARDS patients free IGF‐I serum levels are significantly lower than control individuals ƒP < 0.0001, 95% CI.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4255805&req=5

fig01: Free (Active) IGF‐I Protein Levels in ELF and Serum. Free IGF‐I protein levels were measured in BALF and serum by RIA. ELF concentration was calculated using the urea method to correct for BAL dilution as described in Materials and Methods. (A) Free IGF‐I protein levels are elevated in FP‐ARDS ELF (n = 14) versus control individuals (n = 11), *P < 0.05, 95% CI and versus early ALI/ARDS ELF (n = 11), #P < 0.05, 95% CI. (B) In early ALI/ARDS serum (n = 11) free IGF‐I protein levels increase significantly compared to control (n = 11), *P < 0.0001 and FP‐ARDS patients (n = 14) #P < 0.0001. In FP‐ARDS patients free IGF‐I serum levels are significantly lower than control individuals ƒP < 0.0001, 95% CI.

Mentions: Free IGF‐1 levels were determined in the ELF and serum of control, ALI/ARDS and FP‐ARDS patients. Figure 1A shows a significant increase in free IGF‐I levels in the ELF of FP‐ARDS patients (13.9 ± 4.8 ng/mL) compared to early ALI/ARDS (0.8 ± 0.3 ng/mL) and control (0.5 ± 0.1 ng/mL) groups. In several control BAL specimens the level of free IGF‐I protein was below the detection limit of the assay (0.06 ng/mL). For these samples, a value of 0.06 ng/mL was recorded for IGF‐I concentration and used to calculate the mean ELF concentration of free IGF‐I. These results are consistent with our previous findings where IGF‐I immunoreactivity was enhanced in FP‐ARDS patients (Krein et al. 2003). On the other hand, serum free IGF‐I levels were elevated in the early ALI/ARDS group (569.2 ± 83.5 ng/mL) compared to the levels recovered in the controls (129.5 ± 17.8 ng/mL) and FP‐ARDS group (50.6 ± 4.8 ng/mL) (Fig. 1B). These results are consistent with previous reports of reduced IGF‐I production from the liver during sustained inflammation, such as occurring during FP‐ARDS (ARDS ≥ 5 days) (Thissen and Verniers 1997).


Enhanced production of IGF-I in the lungs of fibroproliferative ARDS patients.

Andonegui G, Krein PM, Mowat C, Brisebois R, Doig C, Green FH, Léger C, Winston BW - Physiol Rep (2014)

Free (Active) IGF‐I Protein Levels in ELF and Serum. Free IGF‐I protein levels were measured in BALF and serum by RIA. ELF concentration was calculated using the urea method to correct for BAL dilution as described in Materials and Methods. (A) Free IGF‐I protein levels are elevated in FP‐ARDS ELF (n = 14) versus control individuals (n = 11), *P < 0.05, 95% CI and versus early ALI/ARDS ELF (n = 11), #P < 0.05, 95% CI. (B) In early ALI/ARDS serum (n = 11) free IGF‐I protein levels increase significantly compared to control (n = 11), *P < 0.0001 and FP‐ARDS patients (n = 14) #P < 0.0001. In FP‐ARDS patients free IGF‐I serum levels are significantly lower than control individuals ƒP < 0.0001, 95% CI.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4255805&req=5

fig01: Free (Active) IGF‐I Protein Levels in ELF and Serum. Free IGF‐I protein levels were measured in BALF and serum by RIA. ELF concentration was calculated using the urea method to correct for BAL dilution as described in Materials and Methods. (A) Free IGF‐I protein levels are elevated in FP‐ARDS ELF (n = 14) versus control individuals (n = 11), *P < 0.05, 95% CI and versus early ALI/ARDS ELF (n = 11), #P < 0.05, 95% CI. (B) In early ALI/ARDS serum (n = 11) free IGF‐I protein levels increase significantly compared to control (n = 11), *P < 0.0001 and FP‐ARDS patients (n = 14) #P < 0.0001. In FP‐ARDS patients free IGF‐I serum levels are significantly lower than control individuals ƒP < 0.0001, 95% CI.
Mentions: Free IGF‐1 levels were determined in the ELF and serum of control, ALI/ARDS and FP‐ARDS patients. Figure 1A shows a significant increase in free IGF‐I levels in the ELF of FP‐ARDS patients (13.9 ± 4.8 ng/mL) compared to early ALI/ARDS (0.8 ± 0.3 ng/mL) and control (0.5 ± 0.1 ng/mL) groups. In several control BAL specimens the level of free IGF‐I protein was below the detection limit of the assay (0.06 ng/mL). For these samples, a value of 0.06 ng/mL was recorded for IGF‐I concentration and used to calculate the mean ELF concentration of free IGF‐I. These results are consistent with our previous findings where IGF‐I immunoreactivity was enhanced in FP‐ARDS patients (Krein et al. 2003). On the other hand, serum free IGF‐I levels were elevated in the early ALI/ARDS group (569.2 ± 83.5 ng/mL) compared to the levels recovered in the controls (129.5 ± 17.8 ng/mL) and FP‐ARDS group (50.6 ± 4.8 ng/mL) (Fig. 1B). These results are consistent with previous reports of reduced IGF‐I production from the liver during sustained inflammation, such as occurring during FP‐ARDS (ARDS ≥ 5 days) (Thissen and Verniers 1997).

Bottom Line: Our data show that IGF-I is significantly increased in the ELF in FP-ARDS patients.A significant correlation between IGF-I and PCP-III in the ELF of FP-ARDS patients is found.Our data suggest that IGF-I found in the lungs of FP-ARDS patients results from both increased lung permeability and local production of IGF-I.

View Article: PubMed Central - PubMed

Affiliation: Department of Critical Care Medicine, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada Immunology Research Group, Faculty of Medicine, University of Calgary Health Research Innovation Center, Calgary, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus